Mechanisms of the development of androgen independence in prostate cancer

World Journal of Urology

Volumn 23, Issue 1, 2005, Pages 1-9

  So, Alan ^a   Gleave, Martin ^a   Hurtado Col, Antonio ^a   Nelson, Colleen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Androgen independence; Hormone refractory prostate cancer; Prostate cancer

Indexed keywords

ANDROGEN; ANDROSTENEDIOL; ANTISENSE OLIGONUCLEOTIDE; CLUSTERIN; CORTISONE; CYPROTERONE ACETATE; ESTRADIOL; FLUTAMIDE; HEAT SHOCK PROTEIN 27; NILUTAMIDE; PROGESTERONE; PROTEIN BCL 2; PROTEIN BCL XL;

CANCER CELL; CELL CLONE; CELL HETEROGENEITY; CELL PROLIFERATION; CELL SELECTION; CELL STIMULATION; CELL SUBPOPULATION; CELL SURVIVAL; DRUG RESPONSE; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; EVOLUTIONARY ADAPTATION; GENE CONTROL; GENOMIC INSTABILITY; HUMAN; MALE; PATHOPHYSIOLOGY; PHENOTYPE; PROSTATE CANCER; REVIEW;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENES; RECEPTORS, ANDROGEN; TREATMENT OUTCOME;

EID: 15844429706     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-004-0473-1     Document Type: Review

References (88)

1. Isaacs JT (1999) The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 26:263-273
2. Graff JR (2002) Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin Ther Targets 6:103-113
3. Bostwick DG et al. (1998) Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma. Cancer 83:1995-2002 10.1002/ (SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2
4. Craft N et al. (1999) Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59:5030-5036
5. Ettinger SL et al. (2004) Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64:2212-2221
6. Visakorpi T et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406 10.1038/ng0495-401
7. Edwards J et al. (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552-556 10.1038/sj.bjc.6601127
8. Latil A et al. (2001) Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61:1919-1926 1:CAS:528:DC%2BD3MXit1Ogsrw%3D
9. Linja MJ et al. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555
10. Ruizeveld de Winter J.A et al. (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735-746
11. Brown RS et al. (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198:237-244 10.1002/path.1206
12. Palmberg C et al. (2000) Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164:1992-1995 10.1097/ 00005392-200012000-00029
13. Chen CD et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39 10.1038/nm972
14. Gregory CW et al. (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898
15. Gregory CW et al. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319
16. Koh E, Kanaya J, Namiki M (2001) Adrenal steroids in human prostatic cancer cell lines. Arch Androl 46:117-125 10.1080/01485010151094010
17. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45 10.1038/35094009
18. Newmark JR et al. (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A 89:6319-6323
19. Marcelli M et al. (2000) Androgen receptor mutations in prostate cancer. Cancer Res 60:944-949
20. Taplin ME et al. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515 1:CAS:528:DyaK1MXjs1yms7Y%3D
21. Taplin ME et al. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398 10.1056/NEJM199505253322101
22. Koivisto PA et al. (1999) Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clin Cancer Res 5:3578-3582
23. Veldscholte J et al. (1992) The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41:665-669 10.1016/0960-0760(92)90401-4
24. Suzuki H et al. (1996) Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome. Prostate 29:153-158
25. Fenton MA et al. (1997) Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 3:1383-1388
26. Culig Z et al. (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550 10.1210/me.7.12.1541
27. Zhao XY et al. (2000) Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6:703-706 10.1038/76287
28. Kelly WK (1998) Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol 34 [Suppl 3]:18-23
29. Yeh S, Chang C (1996) Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A 93:5517-5521 10.1073/pnas.93.11.5517
30. Miyamoto H et al. (1998) Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci U S A 95:7379-7384 10.1073/ pnas.95.13.7379
31. Gregory CW et al. (1998) Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58:5718-5724
32. Fujimoto N et al. (1999) Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 274:8316-8321 10.1074/jbc.274.12.8316
33. Bakin RE et al. (2003) Constitutive activation of the Ras/ mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63:1981-1989
34. Gnanapragasam VJ et al. (2001) Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85:1928-1936 10.1054/bjoc.2001.2179
35. Ueda T, Bruchovsky N, Sadar MD (2002) Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277:7076-7085 10.1074/jbc.M108255200
36. Culig Z et al. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478
37. Culig Z et al. (1997) Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate 32:106-114 10.1002/ (SICI)1097-0045(19970701)32:2<106::AID-PROS5>3.0.CO;2-K
38. Jongsma J et al. (2000) Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 42:34-44 10.1002/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2
39. Craft N et al. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/ neu tyrosine kinase. Nat Med 5:280-285 10.1038/6495
40. Hobisch A et al. (1998) Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58:4640-4645
41. Signoretti S et al. (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92:1918-1925 10.1093/jnci/92.23.1918
42. Shi Y et al. (2001) Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 166:1514-1519 10.1097/ 00005392-200110000-00083
43. Wen Y et al. (2000) HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841-6845
44. Zhou BP et al. (2000) HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275:8027-8031 10.1074/jbc.275.11.8027
45. Halvorsen OJ, Haukaas SA, Akslen LA (2003) Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 9:1474-1479 1:CAS:528:DC%2BD3sXislertbw%3D
46. Zhou H et al. (2000) Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 151:483-494 10.1083/jcb.151.3.483
47. Kulik G, Klippel A, Weber MJ (1997) Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 17:1595-1606
48. Li J, DeFea K, Roth RA (1999) Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. J Biol Chem 274:9351-9356 10.1074/jbc.274.14.9351
49. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34 10.1210/ er.16.1.3
50. Cohen P, Peehl DM, Rosenfeld RG (1994) The IGF axis in the prostate. Horm. Metab. Res. 26 81-84
51. Grimberg A, Cohen P (2000) Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183:1-9
52. Thomas LN et al. (2000) Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5. Prostate 42:203-210
53. Cohen P et al. (1994) Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142:407-415
54. Miyake H, Pollak M, Gleave ME (2000) Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60:3058-3064
55. Kiyama S et al. (2003) Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63:3575-3584
56. Miyake H et al. (2000) Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141:2257-2265 10.1210/en.141.6.2257
57. McDonnell TJ et al. (1997) Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157:569-574 10.1097/00005392-199702000-00042
58. Raffo AJ et al. (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 155:4438-4445
59. Herbst RS, Frankel SR (2004) Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): A rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 10:4245s-4248s
60. Hakansson A et al. (2003) Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy. Cancer Immunol Immunother 52:249-254
61. Chanan-Khan A, Czuczman MS (2004) Bcl-2 antisense therapy in B-cell malignant proliferative disorders. Curr Treat Options Oncol 5:261-267
62. Leung S et al. (2001) Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 91:846-850 10.1002/ 1097-0215(200002)9999:9999<::AID-IJC1131>3.0.CO;2-Y
63. Miayake H, Tolcher A, Gleave ME (2000) Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 92:34-41 10.1093/jnci/92.1.34
64. Miyake H, Monia BP, Gleave ME (2000) Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 86 :855-862
65. Steinberg J et al. (1997) Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3:1707-1711
66. Cervellera M et al. (2000) Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol Chem 275:21055-21060 10.1074/jbc.M002055200
67. Kyprianou N et al. (1991) Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51:162-166
68. Redondo M et al. (2000) Overexpression of clusterin in human breast carcinoma. Am J Pathol 157:393-399
69. Wellmann A et al. (2000) Detection of differentially expressed genes in lymphomas using cDNA arrays: Identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 96:398-404
70. Parczyk K et al. (1994) Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol 120:186-188
71. Calero M et al. (2000) Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech 50:305-315
72. Rosenberg ME, Silkensen J (1995) Clusterin: Physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 27:633-645 10.1016/1357-2725(95)00027-M
73. Montpetit ML, Lawless KR, Tenniswood M (1986) Androgen-repressed messages in the rat ventral prostate. Prostate 8:25-36
74. Miyake H et al. (2000) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60:170-176
75. Bubendorf L et al. (1999) Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91:1758-1764 10.1093/jnci/91.20.1758
76. July LV et al. (2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50:179-188 10.1002/pros.10047
77. Tenniswood MP et al. (1992) Active cell death in hormone-dependent tissues. Cancer Metastasis Rev 11:197-220 10.1007/BF00048064
78. Danik M et al. (1991) Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc Natl Acad Sci U S A 88:8577-8581
79. Connor J et al. (1991) SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int 39:1098-1103
80. Ho SM et al. (1998) Lack of association between enhanced TRPM-2/ clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am J Pathol 153:131-139
81. Schwochau GB, Nath KA, Rosenberg ME (1998) Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int 53:1647-1653 10.1046/j.1523-1755.1998.00902.x
82. French LE et al. (1992) Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J Clin Invest 90:1919-1925
83. Wilson MR Easterbrook-Smith SB (2000) Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 25:95-98 10.1016/S0968-0004(99)01534-0
84. Humphreys DT et al. (1999) Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274:6875-6881 10.1074/ jbc.274.11.6875
85. Sensibar JA et al. (1995) Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 55:2431-2437
86. Miyake H et al. (2000) Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 60:2547-2554
87. Miyake H et al. (2003) Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep 10:469-473
88. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M (2004) Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64:6595-65602